[go: up one dir, main page]

ES2054718T3 - El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica. - Google Patents

El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.

Info

Publication number
ES2054718T3
ES2054718T3 ES88103184T ES88103184T ES2054718T3 ES 2054718 T3 ES2054718 T3 ES 2054718T3 ES 88103184 T ES88103184 T ES 88103184T ES 88103184 T ES88103184 T ES 88103184T ES 2054718 T3 ES2054718 T3 ES 2054718T3
Authority
ES
Spain
Prior art keywords
gepirone
preparation
treatment
pharmaceutical composition
atypical depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88103184T
Other languages
English (en)
Inventor
Jerry M Cott
Neil Kurtz
Donald S Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2054718T3 publication Critical patent/ES2054718T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA GEPIRONA Y SUS SALES FARMACEUTICAMENTE ACEPTABLES SON UTILES PARA MEJORAR ALGUNAS ENFERMEDADES DEPRESIVAS PRIMARIAS, TALES COMO LA DEPRESION PRINCIPAL CON MELANCOLIA Y LA DEPRESION ATIPICA.
ES88103184T 1987-03-02 1988-03-02 El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica. Expired - Lifetime ES2054718T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/020,922 US4771053A (en) 1987-03-02 1987-03-02 Method for alleviation of primary depressive disorders

Publications (1)

Publication Number Publication Date
ES2054718T3 true ES2054718T3 (es) 1994-08-16

Family

ID=21801308

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88103184T Expired - Lifetime ES2054718T3 (es) 1987-03-02 1988-03-02 El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.

Country Status (8)

Country Link
US (1) US4771053A (es)
EP (1) EP0282818B1 (es)
JP (1) JPH0667842B2 (es)
AT (1) ATE107168T1 (es)
AU (1) AU609781B2 (es)
CA (1) CA1313138C (es)
DE (1) DE3850154T2 (es)
ES (1) ES2054718T3 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US7028049B1 (en) * 1996-02-17 2006-04-11 Allcare Health Management System, Inc. Standing order database search system and method for internet and internet application
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) * 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
CN102918031A (zh) 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel

Also Published As

Publication number Publication date
AU609781B2 (en) 1991-05-09
JPH0667842B2 (ja) 1994-08-31
CA1313138C (en) 1993-01-26
EP0282818B1 (en) 1994-06-15
EP0282818A3 (en) 1990-10-24
ATE107168T1 (de) 1994-07-15
DE3850154T2 (de) 1994-10-27
AU1257588A (en) 1988-09-01
EP0282818A2 (en) 1988-09-21
DE3850154D1 (de) 1994-07-21
JPS63243028A (ja) 1988-10-07
US4771053A (en) 1988-09-13

Similar Documents

Publication Publication Date Title
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2069582T3 (es) Nucleosidos terapeuticos.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2053429T3 (es) El uso de buspirona para la preparacion de composiciones farmaceuticas para aliviar la ansiedad fobica.
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2080307T3 (es) Composiciones farmaceuticas.
ES2179193T3 (es) Combinaciones sinergicas de zidovudina, 1592u89 y 3tc.
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
ATE50499T1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
ES2051733T3 (es) Procedimiento de obtencion de un medicamento a base de tamoxifen para uso local.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ATE99945T1 (de) Verwendung von 5'-deoxy-5'-methylthioadenosin s- adenosylmethionin und dessen salzen zur herstellung von seborrhea vermindernden arzneimitteln.
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
ES2040239T3 (es) Procedimiento de preparacion de una composicion farmaceutica para la profilaxis y terapia de la ulcera gastrica.
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
ES2087279T3 (es) El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 282818

Country of ref document: ES